Making the difference
Xenikos is continually looking to enlarge its clinical footprint by expanding its research and development program. As well as expanding the extent of clinical trials in size and geographical coverage, it is also planning to further explore the potential of its products in treating other clinical indications, in which, T-cells play a crucial role, such as solid organ rejection and severe autoimmune diseases. Forming partnerships that can help support and advance portions of the clinical research program is a high priority.
In addition, joining forces with organizations and associations and fostering close links with research, industry, healthcare professionals and the medical authorities that shape the healthcare landscape is important to ensure that Xenikos contributes as much as possible to medicine.
“Partnerships help us advance more quickly. Together with others we can strengthen our commitment to making a difference in the lives of patients with serious immune diseases.”
– Ypke van Oosterhout, CEO, Xenikos
Xenikos is interested in discussing strategic collaborations on internal programs or apply its technologies against novel targets with serious potential partners.
Startups Radboudumc succesvol in 2018
Health Valley: een terugblik op 2018
Dutch Company Xenikos Secures USD 30 Million in Series B Financing
Is dit bedrijf voor jou een potentiële match? Neem dan contact op met:
Mirjam van den Bosch
Naar onze partners
Health Valley Netherlands gebruikt cookies om het gebruik van de website te analyseren en het gebruiksgemak te verbeteren. Lees meer over cookies.